Canagliflozin

Drug Profile

Canagliflozin

Alternative Names: Canagliflozin-hydrate; Canaglu; Invokana; JNJ-28431754; Sulisent; TA-7284

Latest Information Update: 12 Jul 2017

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Developer Daiichi Sankyo Company; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies
  • Phase II Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 30 Jun 2017 Mitsubishi Tanabe completes a clinical trial in Type 2 diabetes mellitus in Japan (UMIN000018814)
  • 13 Jun 2017 Efficacy and safety data from the phase III CANVAS and CANVAS-R trial in Type 2 diabetes mellitus released by Janssen
  • 12 Jun 2017 Registered for Type-2 diabetes mellitus in Azerbaijan, Bahrain, Egypt, Ghana, Honduras, Morocco, Oman, Saudi Arabia, Thailand, Malaysia, Ukraine (PO) before June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top